True. Any agreement that gives up CX-1739 would be worse than a sale of the Company--so we agree on that. $3 million without CX-1739 would be pointless. I don't expect to see that--IF they are able to raise some money, and in my view, they probably can, but the less, the better--they will either partner in the service of then running an ADHD trial with CX-1739--or they sell the Company. The only path forward at this point for Cortex as an independent company is going for ADHD with CX-1739, and they have to find a way to partner while keeping CX-1739 in order to do so. Not easily done (obviously, or it would have been already completed). The only alternative would be to sell the Company. We'll see which way it goes.
NeuroInvestment
News 
Market Data 
Discover 
AI
